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Assessing Chronic Opioid Management at an Internal 
Medicine-Pediatrics Clinic 
 
Anh-Thu Tiffany Vu, Jeremiah Cheng 
Introduction:  
The number of deaths attributed to synthetic 
opioids has nearly tripled in the US from 
1999 to 2014. Although there is limited 
evidence regarding the effectiveness of 
long-term opioid therapy for chronic pain, a 
condition estimated to affect 11.2% of the 
US adult population; opioids are often 
prescribed for this reason in the outpatient 
setting. The CDC has produced guidelines 
regarding safe opioid prescribing methods, 
however changes are also necessary within 
clinic systems to improve the safety and 
management of opioid prescriptions This is 
particularly important in resident led clinics 
where multiple providers often see patients 
over the course of their care. Our quality 
improvement (QI) project aimed to 
standardize clinic workflow and 
management of chronic opioid prescription 
by implementing routine surveillance 
screening and creating a new patient survey. 
Providers were also encouraged to do the 
following: 1) update problem lists, 2) 
document specific surveillance dates and 
signed agreements, and 3) utilize a pre-made 
progress note template to address specific 
concerns with chronic opioid use. 
Methods: 
On 10/1/16 the QI group introduced the 
following routine surveillance suggestions to 
clinic: 1) requiring an annually signed 
chronic pain agreement, 2) urine drug screen 
(UDS) collection at least every 6 months, 3) 
Controlled Substance Utilization Review 
and Evaluation System (CURES) report 
checked at every clinic visit. A template for 
chronic pain visits was created and shared 
with all clinic providers in an effort to 
improve these measures. Data was collected 
on clinic patients one year prior to 
implementation of the QI group 
interventions (10/1/15 - 10/1/16) and six 
months after implementation (10/1/16 -
6/1/17). To identify patients on chronic 
opioid therapy, an Epic report was 
generated, which filtered for specific pre-
determined ICD-9 codes. Additionally, a 
physical list was kept in clinic on which 
providers would document the MRN and 
visit date of a patient who was on chronic 
opioid therapy. Eligible patients were 
flagged for any of the following if occurred 
during the collection time period: 1) pain 
agreement signed in the past 1 year, 2) 
weaning opiate therapy discussed, 3) 
CURES report checked, 4) UDS screen 
ordered in the past 6 months, 5) abnormal 
UDS/CURES report documented, and 6) 
alternate therapies discussed. 
Results: 
Pre-intervention data was collected from 
10/01/15 to 10/01/16 (n=56). Pre-
intervention data showed the following: 
25.4% of encounters had documentation of a 
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pain agreement within the last year, 35.4% 
of encounters documented that weaning was 
discussed, 21.4% of encounters documented 
that CURES was checked or mentioned, and 
37.5% of encounters documented that a 
screening UDS was performed within the 
last six months. Of 39 patients with 
documented UDS or CURES, 9 (23.0%) had 
a documented abnormal report. 
Post-intervention data was collected from 
10/01/16 to 06/01/17 (n=37) and showed the 
following: 72.2% of encounters documented 
a pain agreement within the last year, 81.0% 
of encounters documented a discussion of 
weaning medications, 88.5% of encounters 
documented that CURES was checked or 
mentioned, and 80.5% of encounters had 
documented that a screening UDS was 
performed within the last 6 months. Of 27 
post-intervention patients, 12 patients 
(44.4%) had a documented abnormal UDS 
or CURES. 
There were statistically significant 
differences in encounters documenting a 
pain agreement within the last year 
(p<0.001), encounters in which weaning was 
discussed and documented (p<0.001), 
encounters in which CURES was checked or 
mentioned and documented (p<0.001), and 
encounters in which there was 
documentation that a screening UDS was 
performed within the last six months 
(p=0.001). There was not, however, a 
statistically significant difference in the 
percentage of encounters in which UDS or 
CURES was abnormal (p=0.22). 
Conclusions: 
The QI intervention shows a statistically 
significant increase in provider compliance 
to a new clinic-specific standardized 
workflow and management practice for 
opioid prescriptions given to chronic opioid 
users. This, however, did not result in a 
decrease in the number of patients with an 
abnormal UDS or CURES though data was 
only collected for a six-month period after 
the intervention began. 
The data was fully dependent upon 
documentation by the provider, which 
creates the possibility of introducing bias 
into results. As compliance with the 
progress note template increases, the degree 
of error arising from the assumption of the 
correlation of documentation and real 
practice should decrease accordingly. 
Primary care physicians are responsible for a 
significant burden of opioid prescriptions. 
Introducing a new opioid-centered clinic 
template improved clinic workflow and 
potentially may lead to safer prescribing 
methods. These efforts reflect an effort to 
minimize prescription opiate abuse. The 
next steps in our QI project aims to evaluate 
safety and efficacy by utilizing information 
that will now be documented in every 
chronic pain clinic visit, specifically 
morphine equivalents, PEG scores, 
concurrent benzodiazepine use, and 
concomitant high risk diseases (alcohol 
abuse, depression, anxiety). 
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